Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**A244_N332-rgp120** is a recombinant glycoprotein 120 (rgp120) envelope protein variant derived from the HIV-1 CRF01_AE A244 isolate, engineered with an N-linked glycosylation site shifted from N334 to N332 to enrich high-mannose glycans (primarily Man5). Produced in MGAT1- CHO cells to limit complex glycosylation and sialic acid content, it exhibits improved binding to broadly neutralizing monoclonal antibodies (bN-mAbs) such as PG9 (V1V2 apex), PGT128 and PGT126 (N301/N332 glycans), and 10-1074 (N332-restricted) compared to standard CHO-produced A244-rgp120 used in the RV144 trial. Yields exceed 1 g/L in stable cell lines like 5F MGAT1-CHO, addressing production bottlenecks for HIV vaccine antigens. It aims to enhance immunogenicity over prior rgp120 vaccines by presenting glycan-dependent epitopes absent in complex-glycan versions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on A244_N332-rgp120.